Health

FDA Approves HIV-Prevention Drug That Nearly Eliminated the Virus’s Spread in Clinical Trials

The twice-a-year HIV prevention shot from Gilead has won regulatory approval after trials showed near-total protection.
FDA Approves HIV-Prevention Drug That Nearly Eliminated the Virus’s Spread in Clinical Trials
Gilead Sciences headquarters in Foster City, Calif., on April 29, 2020. Justin Sullivan/Getty Images
Tom Ozimek
Tom Ozimek
Reporter
|Updated:
0:00

Gilead Sciences announced on June 18 that the Food and Drug Administration (FDA) has approved its twice-a-year shot to prevent HIV, with company executives touting the medication as a “very real opportunity” at ending the HIV epidemic.

In a statement, Gilead said that clinical trials of the drug—called Yeztugo or lenacapavir—showed that the twice-yearly injection was highly effective, with nearly all study participants who took it remaining HIV negative.
Tom Ozimek
Tom Ozimek
Reporter
Tom Ozimek is a senior reporter for The Epoch Times. He has a broad background in journalism, deposit insurance, marketing and communications, and adult education.
twitter